Synaptogenix Inc (SNPX)

[Cyosol]

They'll probably just throw out a PR like for the previous trials. They announced a conference call before releasing "positive" results in 2017 and announced the results straight away in the PR for negative results in 2019.

Topline data should show patient scores after receiving the last dose and full data should show their scores after not receiving the drug for several months to see if any improvements linger.

If they can show improvement in the topline data that would be good news on its own, but if the full data maintains those improved scores that would be a sign that the drug not only benefits patients but that the benefits are also long-lasting.

As for shots on goal, I'd say it depends on how the topline data looks. The drug has never been tested in a longer trial like this so nobody knows what scores could look like after the first dosing cycle.